Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody

Cell Transplantation
Aaron LiewTimothy O'Brien

Abstract

Intramuscular administration of mesenchymal stromal cells (MSCs) represents a therapeutic option for diabetic critical limb ischemia. Autologous or allogeneic approaches may be used but disease-induced cell dysfunction may limit therapeutic efficacy in the former. Our aim was to compare the efficacy of allogeneic and autologous MSC transplantation in a model of hindlimb ischemia in diabetes mellitus and to determine whether allogeneic transplantation would result in the activation of an immune response. MSCs were isolated from C57BL/6 (B6) and diabetic obese C57BKSdb/db mice. Phosphate-buffered saline (control group), and MSCs (1 × 106) from B6 (allogeneic group) or C57BKSdb/db (syngeneic group) were administered intramuscularly into the ischemic thigh of C57BKSdb/db mice following the induction of hindlimb ischemia. MSCs derived from both mouse strains secrete several angiogenic factors, suggesting that the potential therapeutic effect is due to paracrine signaling. Administration of allogeneic MSCs significantly improved blood perfusion as compared with the control group on week 2 and 3, post-operatively. In comparison with the control group, syngeneic MSCs significantly improved blood perfusion at week 2 only. There was no s...Continue Reading

References

Nov 15, 2011·The Journal of Thoracic and Cardiovascular Surgery·Gabriel P LasalaJose J Minguell
Dec 6, 2011·Transplantation·Kathryn J Wood, Ryoichi Goto
Dec 14, 2011·Journal of Cellular and Molecular Medicine·Sabine SchuThomas Ritter
Apr 14, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Han Cheol LeeJin Sup Jung
Aug 1, 2012·Stem Cell Research & Therapy·Aaron Liew, Timothy O'Brien
Dec 1, 2012·Stem Cells Translational Medicine·Laura Shin, Daniel A Peterson
Dec 29, 2013·Current Opinion in Organ Transplantation·Senthilkumar Alagesan, Matthew D Griffin
Jun 7, 2014·Frontiers in Immunology·Elke EggenhoferMartin J Hoogduijn
Mar 26, 2015·Journal of the American Society of Nephrology : JASN·Ana Konvalinka, Kathryn Tinckam
Jul 15, 2016·Stem Cells Translational Medicine·Lindsay C DaviesKatarina Le Blanc
Nov 17, 2017·Science Translational Medicine·Antonio GalleuFrancesco Dazzi
Dec 20, 2017·Journal of Molecular Endocrinology·L A Bach
Feb 13, 2018·Stem Cells and Development·Andrey RatushnyyLudmila Buravkova
Feb 16, 2018·Immunology and Cell Biology·Senthilkumar AlagesanMatthew D Griffin

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
FACS
Flow cytometry

Software Mentioned

FlowJo
ImageJ
SPSS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.